Trial Profile
Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Iniparib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Sanofi
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 24 Mar 2012 This trial is recruiting in France and England.
- 03 Nov 2011 Status changed from active, no longer recruiting to completed. Initial study results presented at the 2011 European Multidisciplinary Cancer Congress.